Previous 10 | Next 10 |
According to Stock Traders Daily, a 20-year industry veteran, #investors can use the #priceaction in Pavmed Inc. Common Stock (NASDAQ: PAVM) to foretell upcoming changes. A current example is provided below. There are trading plans for PAVM, but the data on this page does ...
PAVmed ([[PAVM]] -1.1%) and its major subsidiary Lucid Diagnostics announce that Lucid’s EsoCheck Esophageal Cell Collection Device with Collect + Protect technology has received CE Mark certification. With this certification, EsoCheck may now be marketed in CE Mark Euro...
NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (“PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, and its major subsidiary Lucid Diagnostics Inc. (“Lucid”), today announced that Lucid...
PAVmed ([[PAVM]] +1.9%) announces that it has received CE Mark certification for its CarpX minimally invasive carpal tunnel device.With CE Mark secured, CarpX may now be marketed in CE Mark European countries, which include the European Economic Area (the EU, Norway, Iceland...
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical device company, today announced that it has received CE Mark certification for its Carp...
Initial NYU experience in 99 patients demonstrated EsoCheck and EsoGuard capable of detecting esophageal precancer in chronic heartburn patients NEW YORK, May 24, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed...
#technicalanalysis provides insights that #fundamentalanalysis cannot. We can use that to our #advantage in Pavmed Inc. Common Stock (NASDAQ: PAVM). Using the data offered below we have a real-time example. Review The technical data for PAVM below, and th...
PAVmed Inc. (PAVM) Q1 2021 Earnings Conference Call May 17, 2021 04:30 PM ET Company Participants Mike Havrilla - Director of Investor Relations Lishan Aklog - Chairman & Chief Executive Officer Dennis McGrath - President & Chief Financial Officer Conference Call Participants Kyle Mik...
Conference call to be held today at 4 :30 P M E D T NEW YORK, May 17, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ ) (the “Company” or “PAVmed”), a highly differentiated, multi-product, commercial-stage medical d...
Dr. David Poppers to present on his initial experience with Lucid’s EsoCheck and EsoGuard NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- PAVmed Inc. (Nasdaq: PAVM, PAVMZ) (“PAVmed” or the “Company”), a highly differentiated, multi-product, comm...
News, Short Squeeze, Breakout and More Instantly...
Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume PR Newswire Quarterly EsoGuard ® test volume increased 31 percent sequentially NEW YORK , July 23, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("L...
Lucid Diagnostics Launches New Corporate Website PR Newswire NEW YORK , July 11, 2024 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and majority-ow...
Lucid Diagnostics Announces Positive Data from its ESOGUARD BE-1 Prospective, International, Multicenter Clinical Validation Study of EsoGuard® Esophageal Precancer Testing in a Screening Population PR Newswire Prospective screening study demonstrates excellent EsoGuard s...